Competitive PressureCompetitive pressures impacted both glucagon and epinephrine, with both down 29% year over year.
Pipeline SetbacksThe company has seen continued setbacks on the pipeline front, including the two most recent CRLs on AMP-007 and AMP-018, which along with AMP-002 were key to offsetting erosion for the generic portfolio.
Revenue DeclineAMPH is facing several headwinds in 2025/2026, which should also pressure margins, with expected significant revenue decline in Glucagon and cautious outlook on epinephrine.